AI therapeutics firm Deep Genomics inks Series B

Toronto-based Deep Genomics, an artificial intelligence therapeutics company, has raised US$40 million in Series B funding.

Toronto-based Deep Genomics, an artificial intelligence therapeutics company, has raised US$40 million in Series B funding. Future Ventures led the round. The capital infusion will be used to develop new treatments for rare genetic diseases and to expand the company’s AI discovery platform.

Source: Press Release